

6<sup>th</sup>

**SLOVENIAN  
CONGRESS OF  
ENDOCRINOLOGY**



SLOVENIAN  
ENDOCRINE  
SOCIETY

SLOVENIAN BONE SOCIETY

Congress with international participation

Bled, November 22<sup>nd</sup>– 24<sup>th</sup>, 2018

**FIRST ANNOUNCEMENT**

**6<sup>th</sup>****SLOVENIAN  
CONGRESS OF  
ENDOCRINOLOGY****Programme Committee**

Tomaž Kocjan (Chair)

Katica Bajuk Studen

Tadej Battelino

Simona Gabersček

Andrej Janež

Mojca Jensterle Sever

Marija Pfeifer

Draženka Pongrac Barlovič

Aleš Skvarča

Andrej Zavratnik

**Organising Committee**

Marija Pfeifer (Chair)

Vilma Urbančič Rován (Secretary)

Maja Ravnik Oblak (Treasurer)

Miro Čokolič

Nadan Gregorič

Urška Kšela

Mojca Lunder

Katarina Mlekuš Kozamernik

**Venue****Rikli Balance Hotel,  
Bled, Slovenia  
November 22<sup>nd</sup>– 24<sup>th</sup>, 2018****Registration:**Registration, payment of registration fee and accommodation booking to be made online at [www.6sek.si](http://www.6sek.si)**Registration fee:**Until September 20<sup>th</sup>: **200 €**  
From September 21<sup>st</sup> till November 19<sup>th</sup>: **250 €**  
From November 20<sup>th</sup> on and at the Congress  
Registration Desk: **300 €****Registration fee includes:**

Access to all congress sessions, congress materials, access to the Opening ceremony and Welcome reception, coffee breaks, lunch on Thursday and Friday, Congress dinner on Friday.

**6<sup>th</sup>****SLOVENIAN  
CONGRESS OF  
ENDOCRINOLOGY**

Preliminary programme

**Thursday, 22<sup>nd</sup> November 2018**Registration opens at 10:00 am**12:00 am – 12:30 am****Male hypogonadism** – plenary lecture

Chairperson: Tadej Battelino

- Testosterone replacement therapy – new insights into risks and benefits (*Marija Pfeifer*)

**12:30 am – 1:00 pm****Diabetes and kidney** – plenary lecture

Chairperson: Draženka Pongrac Barlovič

- Diabetic nephropathy – established paradigms and novel insights (*Per-Henrik Groop, Finland*)

1:00 pm – 2:00 pm Lunch**2:00 pm – 2:30 pm****Satellite symposium** Eli Lilly**2:30 pm – 3:00 pm****Satellite symposium** Amgen**3:00 pm – 4:00 pm****Pathophysiology of diabetes – new insights**

Chairperson: Vilma Urbančič Rován

- Key role of beta cells in normal and pathologic homeostasis of energy rich molecules (*Andraž Stožer*)

- Diabetes – from skeletal muscle perspective (*Sergej Pirkmajer*)
- Pathogenesis of diabetic cerebral microangiopathy (*Fajko F. Bajrovič*)

**4:00 pm – 5:00 pm****Pituitary**

Chairperson: Marija Pfeifer

- Genetics of pituitary tumours (*Donato Iacovazzo, UK*)
- Craniopharyngiomas in Slovenian population (*Primož Kotnik, Mojca Jensterle Sever*)
- Management of prolactinomas during pregnancy (*Katarina Mlekuš Kozamernik*)

5:00 pm – 5:30 pm Coffee break**5:30 pm – 6:00 pm****Congress Opening**

Mahkota Award Ceremony

**6:00 pm – 6:30 pm****Gene therapy** – plenary lecture

Chairperson: Tadej Battelino

- Gene therapy for adrenoleukodystrophy (*Florian Eichler, ZDA*)

**6:30 pm – 7:00 pm****Satellite symposium** Novartis8:00 pm – 9:30 pm Welcome reception

**6<sup>th</sup>****SLOVENIAN  
CONGRESS OF  
ENDOCRINOLOGY**

Preliminary programme

**Friday, 23<sup>rd</sup> November 2018****8:00 am – 9:00 am****Satellite symposium** Astra Zeneca**9:00 am – 10:00 am****Use of modern technologies  
in the treatment of diabetes**

Chairperson: Nataša Bratina

- ... during pregnancy (*Marjeta Tomažič*)
- ... in adults (*Aleš Skvarča*)
- Time in range(s) – TIRs – new clinical reality (*Tadej Battelino*)

**10:00 am – 11:00 am****Thyroid**

Chair: Edvard Pirnat

- Diagnostics of Graves' disease (*Katja Zaletel, Edvard Pirnat*)
- Treatment of Graves' disease (*Simona Gaberšček, Nataša Bedernjak Bajuk, Katica Bajuk Studen*)
- Graves' orbitopathy (*Polona Jaki Mekjavič*)
- Radioiodine treatment in patients with Graves' orbitopathy (*Daša Šfiligoj, Polona Jaki Mekjavič, Simona Gaberšček*)

**11:00 am – 11:30 am** Coffee break**11:30 am – 12:00 am****Osteoporosis – plenary lecture**

Chairperson: Tomaž Kocjan

- Long term treatment of osteoporosis (*Serge Ferrari, Switzerland*)

**12:00 am – 1:00 pm****Fatty liver disease**

Chairperson: Draženka Pongrac Barlovič

- NAFLD in patients with diabetes (*Špela Volčanšek*)
- Treatment of NAFLD (*Draženka Pongrac Barlovič*)
- NAFLD in patients with PCOS (*Djuro Macut, Serbia*)

**1:30 pm – 2:30 pm****Satellite symposium with buffet lunch**

Boehringer - Ingelheim

**2:30 pm – 3:15 pm****Inborn errors of metabolism**

Chairperson: Mojca Žerjav Tanšek

- Broadened screening for inborn errors of metabolism (*Urh Grošelj*)
- Management of inborn errors of metabolism in our region (*Mojca Žerjav Tanšek*)
- Transition of patients with inborn errors of metabolism from paediatric to adult endocrinologist (*Nadan Gregorič*)

**3:15 pm – 4:30 pm****Reproductive endocrinology**

Chairperson: Mojca Jensterle Sever

- Gut-brain axis and metabolism in PCOS (*Bulent Yildiz, Turkey*)

**6<sup>th</sup>****SLOVENIAN  
CONGRESS OF  
ENDOCRINOLOGY**

Preliminary programme

**10:30 am – 11:00 am** Coffee break**11:00 am – 11:30 am****Insulin therapy – plenary lecture**

Chairperson: Andrej Janež

- Modern therapy in type 2 diabetes (*Chantal Mathieu, Belgium*)

**11:30 am – 1:00 pm****Adrenal**

Chairperson: Tomaž Kocjan

- Dynamic testing of the HPA axis (*Eystein Husebye, Norway*)
- Cushing's vs. pseudo-Cushing's syndrome (*Karim Meeran, UK*)
- Management of patients with adrenocortical carcinoma (*Darko Kaštelan, Croatia*)

**1:00 pm – 2:00 pm****Diabetes and vascular disease**

Chairperson: Mišo Šabovič

- Assessment of arterial function in patients with diabetes (*Miodrag Janić*)
- Pharmacological options to improve arterial function in patients with type 1 diabetes (*Mojca Lunder*)
- Genetic markers of atherosclerosis progression in patients with type 2 diabetes (*Aleš Pleskovič*)

- Incretin system as a new treatment target in PCOS patients with high metabolic risk (*Mojca Jensterle Sever, Andrej Janež*)
- Patient tailored approach to treatment for different PCOS phenotypes (*Evanthia Diamanti-Kandarakis, Greece*)

**4:30 pm – 5:00 pm** Coffee break**5:00 pm – 6:00 pm****Bone and calcium**

Chairperson: Andrej Zavrtnik

- New treatments for hypoparathyroidism (*Andrea Palermo, Italy*)
- Iatrogenic hypocalcaemia after treatment with antiresorptive drugs (*Andrej Zavrtnik*)
- Management of low bone mass in primary hyperparathyroidism (*Tomaž Kocjan*)

**6:00 pm – 7:30 pm****Satellite symposium** Novo Nordisk**8:00 pm – 10:00 pm** Congress dinner**Saturday 24<sup>th</sup> November 2018****8:00 am – 9:00 am****Satellite symposium** Sanofi**9:00 am – 10:30 am****Oral presentations**

Chairpersons: Katica Bajuk Studen, Aleš Skvarča

**2:00 pm** Congress closing

Award ceremony and snacks

# 6<sup>th</sup>

## SLOVENIAN CONGRESS OF ENDOCRINOLOGY

Free themes and posters

### Abstract submission guidelines:

You are cordially invited to submit your abstracts and share the knowledge from your field of expertise, e.g. the results of your research or interesting clinical case with endocrinologists, primary care physicians and other congress participants.

The abstracts will be evaluated by the Scientific committee and selected for short oral presentation in the free topics session. The criteria for evaluation include scientific and/or clinical value of the work.

The accepted abstracts not selected for oral presentation will be presented as posters. The first authors of the best oral and poster presentations will be awarded.

The abstract should be structured and without references. The maximum word count is 350. Drugs should be written with generic name.

Any financial support from sponsors or other conflict of interest should be clearly stated at the end of the abstract.

Every abstract must contain names and affiliations of all authors and the e-mail address of the presenting author.

Authors are asked to indicate the preferred form of presentation: oral or poster. Unless stated otherwise, the first author is also the presenting author in case of oral presentation.

The deadline for abstract submission is July 31<sup>st</sup>, 2018. Abstracts should be submitted by e-mail to [abstractssek6@gmail.com](mailto:abstractssek6@gmail.com).

Zdravilo Xultophy® enkrat na dan!

# Napredujte še za en korak

s potrjenimi prednostmi v primerjavi z insulinom

- Znižanje HbA<sub>1c</sub> za 1,8 % v prim. z 1,1 %<sup>1,2</sup>
- Zmanjšanje telesne mase z zdravilom Xultophy® in razlika 3,2 kg<sup>1,2</sup>
- 57 % manjše tveganje za potrjene hipoglikemije<sup>1,2</sup>

pri bolnikih s sladkorno boleznijo tipa 2, neurejenih z insulinom glargin 100 enot/ml<sup>1,2\*</sup>

## Prva kombinacija insulina degludek, dolgodelujočega bazalnega insulinskega analoga, in liraglutida, analoga človeškega GLP-1, v enem injekcijskem penziku

### SKRAJŠAN POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA

Iste zdravilo: Xultophy 100 enot/ml + 3,6 mg/ml raztopina za injiciranje. Sestava: insulin degludek in liraglutid. En ml raztopine vsebuje 100 enot insulina degludek in 3,6 mg liraglutida. En napojen injektibilni penzikel vsebuje 300 enot insulina degludek in 10,8 mg liraglutida v 3 ml raztopine. En odmerna korica vsebuje 1 enoto insulina degludek in 0,336 mg liraglutida. **Indikacije:** Zdravljenje odraslih s sladkorno boleznijo tipa 2. **Odmerek in način uporabe:** Zdravilo Xultophy se uporablja enkrat na dan v obliki subkutane injekcije. Zdravilo Xultophy je treba odmerjati glede na potrebe posameznega bolnika. Pri bolnikih z večjo telesno maso, spremenjeno obliko profileta ali nad sočasnim boleznim bi odmerki morali biti prilagojeni. Bolniki, ki postopno odmerki, naj si zdravilo injicirajo, ko so upravičeni, in postopno nadaljujejo s predloženimi odmerjenimi enotami na dan. Zdravljenje je treba, da med posameznimi injiciranimi zdravili vsaj ena ura. **Kontraindikacije:** Zdravilo Xultophy je kontraindicirano pri bolnikih s sladkorno boleznijo tipa 1, pri bolnikih s sladkorno boleznijo tipa 2, ki so že prejeli zdravljenje s sladkorno boleznijo tipa 2, pri bolnikih s sladkorno boleznijo tipa 2, ki so že prejeli zdravljenje s sladkorno boleznijo tipa 2, pri bolnikih s sladkorno boleznijo tipa 2, ki so že prejeli zdravljenje s sladkorno boleznijo tipa 2. **Varuj se pred:** Zdravilo Xultophy je treba uporabiti previdno pri bolnikih s sladkorno boleznijo tipa 2, ki so že prejeli zdravljenje s sladkorno boleznijo tipa 2. **Medsebojno delovanje z drugimi zdravili:** Zdravilo Xultophy lahko vpliva na delovanje drugih zdravil. **Nosečnost in dojenje:** Zdravilo Xultophy je treba uporabiti previdno pri nosečnicah in doječih ženskah. **Neželeni učinki:** Pri uporabi zdravila Xultophy so bili opazni neželeni učinki. **Prejeto odobrenje:** Zdravilo Xultophy je bilo odobreno za uporabo v Sloveniji leta 2015. **Podrobnejše informacije:** Podrobnejše informacije o zdravilu Xultophy so na voljo pri: Novo Nordisk d.o.o., Srnarova cesta 140, Ljubljana, T 01 810 8700, E info@novonordisk.si, S www.novonordisk.si ali www.novonordisk.com. **Učinki:** Xultophy je zaščiteno blagovno znamko in leži v lasti družbe Novo Nordisk A/S, Denzka. **Skupna zdravilna učinkovina:** Insulin degludek / liraglutid. **Učinki:** Xultophy je zaščiteno blagovno znamko in leži v lasti družbe Novo Nordisk A/S, Denzka. **Skupna zdravilna učinkovina:** Insulin degludek / liraglutid. **Učinki:** Xultophy je zaščiteno blagovno znamko in leži v lasti družbe Novo Nordisk A/S, Denzka. **Skupna zdravilna učinkovina:** Insulin degludek / liraglutid.



Pred predpisovanjem preberite celoten povzetek glavnih značilnosti zdravila Samo za strokovno javnost. Podrobnejše informacije o zdravilu so na voljo pri: Novo Nordisk d.o.o., Srnarova cesta 140, Ljubljana, T 01 810 8700, E info@novonordisk.si, S www.novonordisk.si ali www.novonordisk.com. Xultophy® je zaščiteno blagovno znamko in leži v lasti družbe Novo Nordisk A/S, Denzka. 5/XT0418/0083, april 2018.





ново нордиск®

General Sponsor of the Congress  
Novo Nordisk d.o.o.